Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
9 tulemused
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention describes the new use of HMG-CoA reductase inhibitors as upregulators of Type III endothelial cell Nitric Oxide Synthase. Further, this invention describes methods that employ HMG-CoA reductase inhibitors to treat conditions that result from the abnormally low
Materials and methods for inhibiting mamalian S-nitrosoglutathione reductase
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
Various aspects and embodiments relate generally to materials and methods for inhibiting the enzyme S-nitrosoglutathione reductase (GSNOR) and for diagnosing, studying and treating various conditions and diseases related to the activity of this enzyme.
BACKGROUND
S-nitrosylation of
Aldose reductase inhibitors and uses thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
Aldose reductase inhibitors and uses thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
Aldose reductase inhibitors and uses thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
Aldose reductase inhibitors and uses thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of
Aldose reductase inhibitors and methods of use thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
CETP inhibitors in combination with antihypertensive agents and uses thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
This invention relates to pharmaceutical combinations of a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof; and an antihypertensive agent or a pharmaceutically acceptable salt thereof, optionally in combination with an HMG
Combinations
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
COMBINATIONS
The present invention relates to a combination, especially a pharmaceutical composition, comprising (a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one active ingredient selected from the group consisting of (i) an anti-diabetic agent; (ii) HMG-Co-A
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
